Literature DB >> 23351481

Bone marrow carcinosis in head and neck carcinoma in a young adult.

Katrin Frölich1, Amin Alzoubi, Justus Müller, Norbert Kleinsasser.   

Abstract

Bone marrow carcinosis has been reported as a consequence of several solid tumors. However, in relation to head and neck squamous cell carcinoma, it is an indication of the rarity of the disease that only 2 reported cases exist in the literature. A 36-year-old male patient was admitted with the diagnosis of squamous cell carcinoma on the floor of the mouth. After the exclusion of distant metastatic disease, tumor surgery was performed. After a regular postoperative course over 3 days, the patient complained of progressive pain in the lower back. Extensive workup included position-emission tomography, which detected an enhancement of the bone marrow. Bone marrow biopsy elucidated advanced bone marrow carcinosis. Palliative chemotherapy was recommended, but the patient deteriorated rapidly and died from septic multiorgan failure within 6 weeks after surgery. Thus, bone marrow carcinosis must be considered in patients with head and neck tumor and osseous pain.
Copyright © 2013 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23351481     DOI: 10.1016/j.joms.2012.11.022

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  2 in total

1.  [Analysis of therapy-relevant receptors in bone marrow carcinosis : Comparison of pathological and clinical parameters].

Authors:  G Massenkeil; C Gropp; H Kreipe; K Hussein
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

2.  Case report: Upper arm metastasis of an oral squamous cell carcinoma.

Authors:  Matthias Christian Wurm; Emeka Nkenke; Friedrich-Wilhelm Neukam; Tobias Möst; Rainer Lutz; Falk Wehrhan; Kathrin Brunner; Konstantinos Theodorou Mitsimponas; Philipp Schlechtweg; Cornelius von Wilmowsky
Journal:  BMC Oral Health       Date:  2015-02-15       Impact factor: 2.757

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.